Pharmaceutical Packaging Applications & Studies
-
Advancing Your API To First Human Dose Trials More Efficiently
2/7/2024
Learn how end-to-end support for development and manufacturing, clinical trial services, advanced drug delivery, and commercial packaging can accelerate drug development and time to market.
-
Meeting An Aggressive Go-To-Clinic Timeline
9/27/2023
Finding an outsourcing partner capable of giving your company proper attention and meeting project milestones on schedule is crucial to ensuring patients in need receive treatment in a timely manner.
-
Overcoming The Challenge Of Maintaining Sterility At Low Temperature Storage
3/24/2023
Learn about a biotech company with a recently approved gene therapy product that needed to select a packaging solution to meet their needs for storage at low temperatures and still get to market quickly.
-
How To Ensure Correct Component Selection When Outsourcing To A CMO
3/22/2023
A CMO-recommended lyophilization stopper was contributing to several operational inefficiencies, including sticking and interlocking of stoppers during filling operations. Requalification work was required to make a change.
-
Transforming From Supply-Led To A Demand-Led Model To Support Commercial Gene Therapies
8/3/2021
In gene therapies supply chains, the focus is entirely patient-centric and the ‘volumes’ can often be as low as 1 dose per batch/lot, so the supply and distribution model needs to be much more flexible and precise.
-
Accelerating Results For Healthcare Brands Through Advocacy, Materials Science Expertise And Integrated Packaging Capabilities
4/15/2021
Any change to packaging design for an approved pharmaceutical product is a time consuming, detail-orientated effort, even with small brand-driven changes––so when governments update packaging regulations on a larger scale, a company’s entire product line could be impacted, creating change management projects for sometimes hundreds of items. When Health Canada introduced amendments to the existing Food and Drug Regulations for non-prescription, over-the-counter (OTC) drug products in 2014, pharmaceutical organizations selling products in the Canadian marketplace knew they had a significant challenge to overcome
-
How To Accelerate Global Market Growth With Agile Product Sample Pouching Programs
4/6/2021
A market-leading consumer health products division of a multi-national pharmaceutical company sought to grow their brand with an innovative, new vitamin product. This launch would involve complimentary sample pouches that could be distributed across a range of channels to reach as many consumers as possible. That is where Jones Healthcare Group stepped in.
-
Pharmaceutical Company Quickly Transitions 28 SKUs To Comply With New Labeling Requirements
2/10/2021
A large multi-national pharmaceutical company needed assistance in complying with new Health Canada regulatory requirements for labeling over-the-counter (OTC) products. The project scope required bringing 28 SKUs that varied by dosage form, quantity, primary and secondary packaging, as well as therapeutic area – and each SKU had its own unique packaging demands and timeline to maintain an unaffected retail shelf presence - into compliance with PLL. Read how all 28 SKUs were delivered in accordance with the forecast timelines and the overall project was completed early.
-
Validating The Stability And Durability Of Labels After Thawing From Cryogenic Temperatures
2/26/2019
One important element of working in cryogenic temperatures involves ensuring labels remain intact and securely adhered to packaging after application as product moves from ambient temperatures to cryogenic temperatures to thawing at the point of use. The following study serves as a model for the need to validate label stability and adherence and is an example of the many different types of validation studies we regularly conduct to mitigate risk for customers during all phases of an advanced therapy clinical trial.
-
Microdialysate Microbore Analysis Of Catecholamine And Metabolites
12/12/2011
The analysis of catecholamines and their metabolites from brain microdialysates poses three technical problems: the small sample size generated by this sampling technique, possible low levels of target analytes, and the need to elute an array of compounds in a reasonable period of time.